Print

IGBA letter to FDA regarding their biologics naming proposals

The International Generic and Biosimilar Medicines Association (IGBA), representing member associations from the U.S. (GPhA), Canada (CGPA), Japan (JGA), Jordan (JAPM), Europe (EGA), South Africa (NAPM), and Taiwan (TGPA), as well as associate member associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI), thank for the opportunity to share our thoughts on the important topic of non-proprietary naming of biological products, including biosimilar products.

Read More

 

 

 

 

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

c/o Interexperts SA
Rue des Pierres-du-Niton 17
1207 Geneva, Switzerland

Telephone: +32 (0)2 5346607
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or 
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site